

Biodiversity

Lundbeck does not operate in areas of high biodiversity value. Nor do we source natural resources from suppliers operating under a biodiversity policy or certification scheme e.g. The Forest Stewardship Council (FSC).

Loss of biodiversity is one of the biggest threats to the natural world and Lundbeck takes biodiversity seriously. We seek to reduce our environmental impact by performing risk assessments, optimize processes and use the least harmful substances in our production.

Our commitment

Lundbeck monitor the environmental effects of the active pharmaceutical ingredients in our new medicinal products. By establishing and implementing the necessary biological and physical/chemical studies, we assess the effect on biodiversity to various aquatic organisms as an integral part of our Environmental Risk Assessment process. The knowledge gained is applied to the manufacturing process resulting in the least possible environmental impact.

Lundbeck is not considered a big contributor of microplastics to the environment. The uses of intentionally added microplastics in our pharmaceuticals (tablets) are limited to the use of microcrystalline cellulose. This solid water insoluble polymer falls under the broadly defined category "microplastics". We closely follow the growing global awareness on the matter and proactively collaborate with key stakeholders, like ECHA, to gain additional knowledge on the matter. As for macro plastics, Lundbeck has worked dedicated for numerous years to segregate (both hard and soft) plastic waste for reuse/recycling, as part of our corporate approach on circular economy.

Control invasive species is relevant to Lundbeck, as we use low-risk genetically modified animals and organisms (GMO) in our research and development of new pharmaceuticals. By high ethical standards of animal welfare, we work according to strict legislation, systems and routines to make sure all organisms are kept enclosed in designated laboratories and ensure no GMO-organisms are introduced to our wildlife by accident.

Lundbeck has taken several local initiatives on our production sites to safeguard biodiversity, e.g. wild flowerbeds, replanting forest, nesting boxes for birds, insect hotels and end use of pesticides and fertilizers.

Our future key challenges and opportunities:

- Support and implement local and national initiatives to increase biodiversity.
- Supporting initiatives to improve data quality and minimizing the presence and effects of pharmaceuticals in the environment. E.g. by participating in European and national industry networks to exchange experience.
- Continually minimizing the use of raw materials and the generation of waste by optimizing our processes and recycling of organic compounds.
- Reducing the presence of solvents and pharmaceuticals in wastewater and air emissions by substituting harmful substances and promoting clean emissions from production.
- Developing and maintaining our environmental principles in the Lundbeck Supplier Standards e.g. by auditing our suppliers in environmental issues.
- Keeping an open and honest dialogue with our stakeholders e.g. by reporting our performance in our Sustainability Report and [Carbon Disclosure Project](#) (CDP).

In our latest Sustainability Report on www.lundbeck.com you can read more about our activities and performance.